# Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)

> **NCT02905188** · PHASE1 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 9 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **GENETIC:** GLYCAR T cells
- **DRUG:** Cytoxan
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT02905188
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-28
- **Primary completion:** 2021-11-17
- **Final completion:** 2023-01-06
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-02-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02905188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02905188, "Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02905188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*